HUMAN TUMOR HYPOXIA

人类肿瘤缺氧

基本信息

项目摘要

DESCRIPTION: (Adapted from the applicant's abstract): Normal and tumor tissue hypoxia is associated with heart attack, stroke and cancer and may be a key factor in diabetes and alcohol-induced liver disease. Cancer specialists have long been interested in tissue hypoxia because hypoxic cells are radioresistant due to altered free radical chemistry and chemoresistant due low drug concentration in hypoxic cells that are at or near the limit of drug diffusion. On a more positive note, hypoxic tumor cells might be targets for improved therapy through bioreductive strategies. Finally, hypoxia (or hypoxia/reperfusion) is now recognized as a stress leading to gene expression in normal and tumor tissue that can be beneficial or harmful depending on circumstances. With the heightened interest in hypoxia in both normal and tumor tissue has come an urgent need for versatile and reliable methods for measuring tissue oxygenation. Many techniques have been proposed including hypoxia markers and oxygen microelectrodes. The primary goal of the present proposal is to make the first direct comparison between these two techniques in human tumors in collaboration with investigators at Aarhus University Hospital in Aarhus, Denmark. Such a comparison was called for in a 1992 NIH Oxygen Workshop. Our hypoxia marker will be injected into patients and 8 hours later oxygen electrode measurements made in the tumor followed by tissue biopsy for hypoxia marker binding by immunohistochemical analysis. The hypoxia marker approach lends itself to comparison with other features of tumor physiology related to therapeutic response. One such comparison to be carried out on the same biopsy sample will be with tumor cell proliferation (Ki-67). We believe that the hypoxia marker technique will be useful in radiation and chemotherapy treatment planning; for studies of tissue oxygenation in models of normal tissue pathologies; and, for relating hypoxia to the expression of stress proteins on a microregional basis.
描述:(改编自申请人摘要):正常和肿瘤

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAMES ARTHUR RALEIGH其他文献

JAMES ARTHUR RALEIGH的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAMES ARTHUR RALEIGH', 18)}}的其他基金

Oral Pimonidazole
口服哌莫硝唑
  • 批准号:
    6787522
  • 财政年份:
    2004
  • 资助金额:
    $ 14.45万
  • 项目类别:
HYPOXIA AND GENE EXPRESSION IN HUMAN TUMORS
人类肿瘤中的缺氧和基因表达
  • 批准号:
    6514396
  • 财政年份:
    2001
  • 资助金额:
    $ 14.45万
  • 项目类别:
PET Reagents for Normal and Tumor Tissue Hypoxia
正常组织和肿瘤组织缺氧的 PET 试剂
  • 批准号:
    6403101
  • 财政年份:
    2001
  • 资助金额:
    $ 14.45万
  • 项目类别:
HYPOXIA AND GENE EXPRESSION IN HUMAN TUMORS
人类肿瘤中的缺氧和基因表达
  • 批准号:
    6287363
  • 财政年份:
    2001
  • 资助金额:
    $ 14.45万
  • 项目类别:
HYPOXIA AND GENE EXPRESSION IN HUMAN TUMORS
人类肿瘤中的缺氧和基因表达
  • 批准号:
    6633638
  • 财政年份:
    2001
  • 资助金额:
    $ 14.45万
  • 项目类别:
Molecular Markers for Tissue Hypoxia
组织缺氧的分子标记
  • 批准号:
    6337080
  • 财政年份:
    2001
  • 资助金额:
    $ 14.45万
  • 项目类别:
HUMAN TUMOR HYPOXIA
人类肿瘤缺氧
  • 批准号:
    2012064
  • 财政年份:
    1997
  • 资助金额:
    $ 14.45万
  • 项目类别:
IMMUNOCHEMICAL MARKER FOR TUMOR HYPOXIA
肿瘤缺氧的免疫化学标志物
  • 批准号:
    2545398
  • 财政年份:
    1996
  • 资助金额:
    $ 14.45万
  • 项目类别:
IMMUNOCHEMICAL MARKER FOR TUMOR HYPOXIA
肿瘤缺氧的免疫化学标志物
  • 批准号:
    2009032
  • 财政年份:
    1996
  • 资助金额:
    $ 14.45万
  • 项目类别:
IMMUNOCHEMICAL MARKER FOR TUMOR HYPOXIA
肿瘤缺氧的免疫化学标志物
  • 批准号:
    2112863
  • 财政年份:
    1995
  • 资助金额:
    $ 14.45万
  • 项目类别:

相似海外基金

EFR3: Novel gatekeeper of cell proliferation
EFR3:细胞增殖的新型看门人
  • 批准号:
    DP240102729
  • 财政年份:
    2024
  • 资助金额:
    $ 14.45万
  • 项目类别:
    Discovery Projects
Modulation of cell proliferation by the tumor suppressor protein NRK
肿瘤抑制蛋白 NRK 对细胞增殖的调节
  • 批准号:
    23K08817
  • 财政年份:
    2023
  • 资助金额:
    $ 14.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
MR imaging for the cell proliferation using in vivo click chemistry
使用体内点击化学进行细胞增殖的 MR 成像
  • 批准号:
    23K18279
  • 财政年份:
    2023
  • 资助金额:
    $ 14.45万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Project 1: Determine the mechanisms Cyclin D-Cdk4/6 uses to drive cell proliferation
项目 1:确定 Cyclin D-Cdk4/6 驱动细胞增殖的机制
  • 批准号:
    10867552
  • 财政年份:
    2023
  • 资助金额:
    $ 14.45万
  • 项目类别:
Identification of active components of sillkworm serum exhibiting cell proliferation and elucidation of the mechanism
蚕血清中细胞增殖活性成分的鉴定及其机制的阐明
  • 批准号:
    23KJ1691
  • 财政年份:
    2023
  • 资助金额:
    $ 14.45万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
The Role of Arginine Transport on Pancreatic Alpha Cell Proliferation and Function
精氨酸转运对胰腺α细胞增殖和功能的作用
  • 批准号:
    10678248
  • 财政年份:
    2023
  • 资助金额:
    $ 14.45万
  • 项目类别:
Regulation of Adherent Cell Proliferation by Matrix Viscoelasticity
基质粘弹性对贴壁细胞增殖的调节
  • 批准号:
    10735701
  • 财政年份:
    2023
  • 资助金额:
    $ 14.45万
  • 项目类别:
mRNA selective translational control required for B cell proliferation
B 细胞增殖所需的 mRNA 选择性翻译控制
  • 批准号:
    2757728
  • 财政年份:
    2022
  • 资助金额:
    $ 14.45万
  • 项目类别:
    Studentship
mechanism of cancer cell proliferation in bone microenvironment of renal cell carcinoma
肾细胞癌骨微环境中癌细胞增殖机制
  • 批准号:
    22K09370
  • 财政年份:
    2022
  • 资助金额:
    $ 14.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Decline of tissue stem cell proliferation and differentiation ability by chronic renal failure and preventive effects by omega-3 polyunsaturated fatty acid
慢性肾功能衰竭引起的组织干细胞增殖和分化能力下降及omega-3多不饱和脂肪酸的预防作用
  • 批准号:
    22K05529
  • 财政年份:
    2022
  • 资助金额:
    $ 14.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了